个人中心 - 老虎社区

Hewx

IP属地：未知

帖子 · 15帖子 · 15
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- HewxHewx
  ·2021-06-30
  like pls
  Aerovate Therapeutics IPO: What awaits the biotech firm after market debut?
  The company has revealed plans to list on the Nasdaq Global Market under the ticker symbol AVTE; to
  Aerovate Therapeutics IPO: What awaits the biotech firm after market debut?
  1,843 140
  2
  分享
  举报
- HewxHewx
  ·2021-06-29
  Like pls
  NIO Will Surpass Tesla as China's Top EV Maker, Navellier Says
  NIO (NIO) -Get Report shares rose Monday after Louis Navellier, chief investment officer of money ma
  NIO Will Surpass Tesla as China's Top EV Maker, Navellier Says
  1,584 6
  4
  分享
  举报
- HewxHewx
  ·2021-06-28
  Like pls
  非常抱歉，此主贴已删除
  1,384 3
  7
  分享
  举报
- HewxHewx
  ·2021-06-27
  Pls like
  非常抱歉，此主贴已删除
  1,283 2
  8
  分享
  举报
- HewxHewx
  ·2021-06-26
  Yes back to 300
  非常抱歉，此主贴已删除
  1,259 3
  8
  分享
  举报
- HewxHewx
  ·2021-06-25
  Comment and like please
  Oil Set for Weekly Gain as Focus Turns to Upcoming OPEC+ Meeting
  (Bloomberg) -- Oil is heading for a fifth weekly advance, the longest winning streak since December,
  Oil Set for Weekly Gain as Focus Turns to Upcoming OPEC+ Meeting
  1,288 1
  2
  分享
  举报
- HewxHewx
  ·2021-06-24
  Comment and like
  非常抱歉，此主贴已删除
  1,305 1
  2
  分享
  举报
- HewxHewx
  ·2021-06-24
  Comment
  非常抱歉，此主贴已删除
  1,316 评论
  4
  分享
  举报
- HewxHewx
  ·2021-06-24
  Comment
  非常抱歉，此主贴已删除
  1,229 1
  3
  分享
  举报
- HewxHewx
  ·2021-06-23
  Comment and like please
  非常抱歉，此主贴已删除
  1,216 2
  6
  分享
  举报

热议股票

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3577008891035439","uuid":"3577008891035439","gmtCreate":1613917773315,"gmtModify":1706620614251,"name":"Hewx","pinyin":"hewx","introduction":"","introductionEn":"","signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":1,"tweetSize":15,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"228c86a078844d74991fff2b7ab2428d-1","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资经理虎","description":"证券账户累计交易金额达到10万美元","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"60.56%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"35ec162348d5460f88c959321e554969-2","templateUuid":"35ec162348d5460f88c959321e554969","name":"宗师交易员","description":"证券或期货账户累计交易次数达到100次","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"80.47%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":12,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":153825638,"gmtCreate":1625018197224,"gmtModify":1633945791544,"author":{"id":"3577008891035439","authorId":"3577008891035439","name":"Hewx","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577008891035439","authorIdStr":"3577008891035439"},"themes":[],"htmlText":"like pls","listText":"like pls","text":"like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":140,"repostSize":0,"link":"https://laohu8.com/post/153825638","repostId":"1130740745","repostType":4,"repost":{"id":"1130740745","kind":"news","pubTimestamp":1625017527,"share":"https://www.laohu8.com/m/news/1130740745?lang=&edition=full","pubTime":"2021-06-30 09:45","market":"us","language":"en","title":"Aerovate Therapeutics IPO: What awaits the biotech firm after market debut?","url":"https://stock-news.laohu8.com/highlight/detail?id=1130740745","media":"AlphaStreet","summary":"The company has revealed plans to list on the Nasdaq Global Market under the ticker symbol AVTE; to ","content":"<blockquote>\n The company has revealed plans to list on the Nasdaq Global Market under the ticker symbol AVTE; to offer around 7.2 million shares for $13-15 per share.\n</blockquote>\n<p>The IPO market has continued the bull run so far this year, unfazed by the virus-related uncertainties, with thetechnology and pharma sectorsstealing the limelight mostly. Biotechnology company Aerovate Therapeutics, Inc. is the latest among the healthcare firms preparing to go public.</p>\n<p>In a statement submitted to the Securities and Exchange Commission, the company revealed plans to list on the Nasdaq Global Market under the ticker symbol<b><i>AVTE</i></b>. It will beoffering about 7.2 million sharesat an estimated price of $13-15 per share. Jefferies Group and Cowen are the main book-running managers.</p>\n<p><b>Cardiopulmonary Research</b></p>\n<p>The Boston-based drug-maker, which is focused on the development of therapies for rare cardiopulmonary diseases, was founded in July 2018 by Benjamin Dake who currently serves as its president.<b>The operations are managed by chief executive officer Timothy Noyes, a Merck (NYSE: MRK) veteran who assumed office last month.</b></p>\n<p>The company’s lead program involves the development of a therapy for the treatment of pulmonary arterial hypertension (PAH). The medicine,<i>AV-101</i>, is an inhaler based on tyrosine kinase inhibitor<i>imatinib</i>. PAH is a progressive proliferative disease of the pulmonary vasculature that is characterized by remodeling, constriction, and occlusion of the small pulmonary arteries, leading to high blood pressure.</p>\n<p><img src=\"https://static.tigerbbs.com/2ec3c278a5ee44a50959da085f9212b5\" tg-width=\"2048\" tg-height=\"1617\" referrerpolicy=\"no-referrer\"></p>\n<p><b>New-Gen Drug for PAH</b></p>\n<p><b>Early-stage clinical trials have indicated that</b><b><i>AV-101</i></b><b>is effective in treating patients suffering from PAH by acting directly on the cause of the disease.</b>In phase-II of the trial — designed to assess the safety and tolerability of the drug — around 200 patients will be enrolled. The top-line data from the study is expected in mid-2023.</p>\n<p>Proceeds from the upcoming offering – estimated at $100 million at the midpoint of the price range – will be used mainly for the continued development of<i>AV-101</i>and to meet costs related to its commercial launch. Once it is successfully launched in the U.S, the management would pursue additional indications for the drug and expansion of the pipeline by tapping into new product opportunities. Earlier this month, the company sold around 30 millionpreferred sharesfor $56 million.</p>\n<p><b>Risks</b></p>\n<p>It goes without saying that the outcome of the final clinical trial would be crucial as far as the company’s future is concerned. Obviously, the main risk to the program is the uncertainty surroundingCOVID-19— any potential resurgence of the pandemic might delay the process and lead to cost escalation.<b>Prolonged cost pressures can take a toll on the finances of the company, which is dependent solely on</b><b><i>AV-101</i></b><b>to become profitable.</b>Moreover, Aerovate will have to compete effectively with the likes of Verve Therapeutics to gain meaningful market share.</p>\n<p>Beingan emerging business, Aerovate is yet to generate revenue. In fiscal 2021, it incurred a net loss of $3.33million or $13.79 per share, compared to a loss of $9.61 million or $40.31 per share last year. The improvement reflects a dip in operating expenses, which more than halved annually.</p>","source":"lsy1609745492275","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aerovate Therapeutics IPO: What awaits the biotech firm after market debut?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAerovate Therapeutics IPO: What awaits the biotech firm after market debut?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-30 09:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://news.alphastreet.com/aerovate-therapeutics-ipo-where-the-biotech-firm-is-headed-after-market-debut/><strong>AlphaStreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The company has revealed plans to list on the Nasdaq Global Market under the ticker symbol AVTE; to offer around 7.2 million shares for $13-15 per share.\n\nThe IPO market has continued the bull run so ...</p>\n\n<a href=\"https://news.alphastreet.com/aerovate-therapeutics-ipo-where-the-biotech-firm-is-headed-after-market-debut/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://news.alphastreet.com/aerovate-therapeutics-ipo-where-the-biotech-firm-is-headed-after-market-debut/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1130740745","content_text":"The company has revealed plans to list on the Nasdaq Global Market under the ticker symbol AVTE; to offer around 7.2 million shares for $13-15 per share.\n\nThe IPO market has continued the bull run so far this year, unfazed by the virus-related uncertainties, with thetechnology and pharma sectorsstealing the limelight mostly. Biotechnology company Aerovate Therapeutics, Inc. is the latest among the healthcare firms preparing to go public.\nIn a statement submitted to the Securities and Exchange Commission, the company revealed plans to list on the Nasdaq Global Market under the ticker symbolAVTE. It will beoffering about 7.2 million sharesat an estimated price of $13-15 per share. Jefferies Group and Cowen are the main book-running managers.\nCardiopulmonary Research\nThe Boston-based drug-maker, which is focused on the development of therapies for rare cardiopulmonary diseases, was founded in July 2018 by Benjamin Dake who currently serves as its president.The operations are managed by chief executive officer Timothy Noyes, a Merck (NYSE: MRK) veteran who assumed office last month.\nThe company’s lead program involves the development of a therapy for the treatment of pulmonary arterial hypertension (PAH). The medicine,AV-101, is an inhaler based on tyrosine kinase inhibitorimatinib. PAH is a progressive proliferative disease of the pulmonary vasculature that is characterized by remodeling, constriction, and occlusion of the small pulmonary arteries, leading to high blood pressure.\n\nNew-Gen Drug for PAH\nEarly-stage clinical trials have indicated thatAV-101is effective in treating patients suffering from PAH by acting directly on the cause of the disease.In phase-II of the trial — designed to assess the safety and tolerability of the drug — around 200 patients will be enrolled. The top-line data from the study is expected in mid-2023.\nProceeds from the upcoming offering – estimated at $100 million at the midpoint of the price range – will be used mainly for the continued development ofAV-101and to meet costs related to its commercial launch. Once it is successfully launched in the U.S, the management would pursue additional indications for the drug and expansion of the pipeline by tapping into new product opportunities. Earlier this month, the company sold around 30 millionpreferred sharesfor $56 million.\nRisks\nIt goes without saying that the outcome of the final clinical trial would be crucial as far as the company’s future is concerned. Obviously, the main risk to the program is the uncertainty surroundingCOVID-19— any potential resurgence of the pandemic might delay the process and lead to cost escalation.Prolonged cost pressures can take a toll on the finances of the company, which is dependent solely onAV-101to become profitable.Moreover, Aerovate will have to compete effectively with the likes of Verve Therapeutics to gain meaningful market share.\nBeingan emerging business, Aerovate is yet to generate revenue. In fiscal 2021, it incurred a net loss of $3.33million or $13.79 per share, compared to a loss of $9.61 million or $40.31 per share last year. The improvement reflects a dip in operating expenses, which more than halved annually.","news_type":1,"symbols_score_info":{"AVTE":0.9}},"isVote":1,"tweetType":1,"viewCount":1843,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":159044756,"gmtCreate":1624933155975,"gmtModify":1633946810711,"author":{"id":"3577008891035439","authorId":"3577008891035439","name":"Hewx","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577008891035439","authorIdStr":"3577008891035439"},"themes":[],"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":6,"repostSize":0,"link":"https://laohu8.com/post/159044756","repostId":"1195734655","repostType":4,"repost":{"id":"1195734655","kind":"news","pubTimestamp":1624932851,"share":"https://www.laohu8.com/m/news/1195734655?lang=&edition=full","pubTime":"2021-06-29 10:14","market":"us","language":"en","title":"NIO Will Surpass Tesla as China's Top EV Maker, Navellier Says","url":"https://stock-news.laohu8.com/highlight/detail?id=1195734655","media":"thestreet","summary":"NIO (NIO) -Get Report shares rose Monday after Louis Navellier, chief investment officer of money ma","content":"<p>NIO&nbsp;(<b>NIO</b>) -Get Report&nbsp;shares rose Monday after Louis Navellier, chief investment officer of money manager Navellier, said the Chinese electric-car maker will surpass Tesla&nbsp;(<b>TSLA</b>) -Get Report&nbsp;in China.</p>\n<p>“Another electric vehicle company will eventually displace Tesla as the biggest manufacturer of EVs in China,” he wrote in a commentary.</p>\n<p>“I’m talking about NIO. The reality is that this company is on the verge of dominating the EV market in China and Hong Kong.”</p>\n<p>NIO American depositary receipts recently traded at $49.23, up 9.2%. They have climbed 27% in the past month amid investor enthusiasm for EVs.</p>\n<p>Tesla recently traded at $687.47, up 2.3%, and has gained 9% in the past month.</p>\n<p>As for NIO, “the company boasts that it is the ‘next-generation car company,’ as it designs and manufactures electric vehicles that utilize the latest technologies in connectivity, autonomous driving and artificial intelligence,” Navellier said.</p>\n<p>“The company is also partnering with cutting-edge chip companies like Nvidia&nbsp;(<b>NVDA</b>) -Get Report.”</p>\n<p>Earlier this month,NIO said that \"Gemini\" was the code namefor a new high-end electric-vehicle lineup to be launched next year. The move buried speculation that the Shanghai EV maker was looking to release a less-expensive mass-entry-level electric car.</p>\n<p>NIO supplier JAC Group last month invited bids to build a NIO production line code-named “Gemini” that would produce 60,000 units a year. That sparked speculation that it would be a new entry-level NIO model.</p>\n<p>Also in June,NIO reported a more than 95% year-over-year increasein deliveries for May. Citi analyst Jeff Chung upgraded the stock to buy from neutral while raising his price target to $58.30 from $57.60.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NIO Will Surpass Tesla as China's Top EV Maker, Navellier Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNIO Will Surpass Tesla as China's Top EV Maker, Navellier Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-29 10:14 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/investing/nio-to-surpass-tesla-in-china-electric-vehicles-navellier-says><strong>thestreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>NIO (NIO) -Get Report shares rose Monday after Louis Navellier, chief investment officer of money manager Navellier, said the Chinese electric-car maker will surpass Tesla (TSLA) -Get Report in China....</p>\n\n<a href=\"https://www.thestreet.com/investing/nio-to-surpass-tesla-in-china-electric-vehicles-navellier-says\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉","NIO":"蔚来"},"source_url":"https://www.thestreet.com/investing/nio-to-surpass-tesla-in-china-electric-vehicles-navellier-says","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1195734655","content_text":"NIO (NIO) -Get Report shares rose Monday after Louis Navellier, chief investment officer of money manager Navellier, said the Chinese electric-car maker will surpass Tesla (TSLA) -Get Report in China.\n“Another electric vehicle company will eventually displace Tesla as the biggest manufacturer of EVs in China,” he wrote in a commentary.\n“I’m talking about NIO. The reality is that this company is on the verge of dominating the EV market in China and Hong Kong.”\nNIO American depositary receipts recently traded at $49.23, up 9.2%. They have climbed 27% in the past month amid investor enthusiasm for EVs.\nTesla recently traded at $687.47, up 2.3%, and has gained 9% in the past month.\nAs for NIO, “the company boasts that it is the ‘next-generation car company,’ as it designs and manufactures electric vehicles that utilize the latest technologies in connectivity, autonomous driving and artificial intelligence,” Navellier said.\n“The company is also partnering with cutting-edge chip companies like Nvidia (NVDA) -Get Report.”\nEarlier this month,NIO said that \"Gemini\" was the code namefor a new high-end electric-vehicle lineup to be launched next year. The move buried speculation that the Shanghai EV maker was looking to release a less-expensive mass-entry-level electric car.\nNIO supplier JAC Group last month invited bids to build a NIO production line code-named “Gemini” that would produce 60,000 units a year. That sparked speculation that it would be a new entry-level NIO model.\nAlso in June,NIO reported a more than 95% year-over-year increasein deliveries for May. Citi analyst Jeff Chung upgraded the stock to buy from neutral while raising his price target to $58.30 from $57.60.","news_type":1,"symbols_score_info":{"NIO":0.9,"TSLA":0.9}},"isVote":1,"tweetType":1,"viewCount":1584,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":127843592,"gmtCreate":1624844238016,"gmtModify":1633948101725,"author":{"id":"3577008891035439","authorId":"3577008891035439","name":"Hewx","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577008891035439","authorIdStr":"3577008891035439"},"themes":[],"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/127843592","repostId":"1157825898","repostType":4,"isVote":1,"tweetType":1,"viewCount":1384,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":124833625,"gmtCreate":1624757696267,"gmtModify":1633949059834,"author":{"id":"3577008891035439","authorId":"3577008891035439","name":"Hewx","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577008891035439","authorIdStr":"3577008891035439"},"themes":[],"htmlText":"Pls like","listText":"Pls like","text":"Pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/124833625","repostId":"1172737444","repostType":4,"isVote":1,"tweetType":1,"viewCount":1283,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":125657176,"gmtCreate":1624672882495,"gmtModify":1633949790039,"author":{"id":"3577008891035439","authorId":"3577008891035439","name":"Hewx","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577008891035439","authorIdStr":"3577008891035439"},"themes":[],"htmlText":"Yes back to 300","listText":"Yes back to 300","text":"Yes back to 300","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/125657176","repostId":"1164137597","repostType":4,"isVote":1,"tweetType":1,"viewCount":1259,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":126747726,"gmtCreate":1624586221965,"gmtModify":1633950895331,"author":{"id":"3577008891035439","authorId":"3577008891035439","name":"Hewx","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577008891035439","authorIdStr":"3577008891035439"},"themes":[],"htmlText":"Comment and like please","listText":"Comment and like please","text":"Comment and like please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/126747726","repostId":"1144285047","repostType":4,"repost":{"id":"1144285047","kind":"news","pubTimestamp":1624586033,"share":"https://www.laohu8.com/m/news/1144285047?lang=&edition=full","pubTime":"2021-06-25 09:53","market":"us","language":"en","title":"Oil Set for Weekly Gain as Focus Turns to Upcoming OPEC+ Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=1144285047","media":"Bloomberg","summary":"(Bloomberg) -- Oil is heading for a fifth weekly advance, the longest winning streak since December,","content":"<p>(Bloomberg) -- Oil is heading for a fifth weekly advance, the longest winning streak since December, as stockpiles shrink and the market tightens ahead of an OPEC+ meeting that will consider pumping more crude.</p>\n<p>Front-month futures in New York are up more than 2% this week and global benchmark Brent is at the highest level since October 2018. The alliance, led by Saudi Arabia and Russia, are set to meet July 1 and the group is widely expected to revive more output in August, according to a Bloomberg survey. Delegates from the coalition say discussions are already underway.</p>\n<p>The rebound in fuel consumption in key regions including the U.S. and Europe is rapidly draining stockpiles, with some flagging the possibility of benchmark Brent crude hitting $100 a barrel again. The prospect of an imminent surge of Iranian oil is also diminishing as talks to revive a nuclear deal drag on.</p>\n<p>The prompt timespread for Brent was 75 cents in backwardation -- where near-dated contracts are more expensive than later-dated ones. The bullish structure has eased from 85 cents at the start of the week.</p>\n<p>Russia is considering making a proposal that OPEC+ boost output and delegates say a hike is being informally discussed. The average gain forecast by analysts was for about 550,000 barrels a day -- barely a quarter of the global supply deficit that the alliance anticipates during August.</p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Oil Set for Weekly Gain as Focus Turns to Upcoming OPEC+ Meeting</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOil Set for Weekly Gain as Focus Turns to Upcoming OPEC+ Meeting\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-25 09:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/oil-set-weekly-gain-focus-233523836.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Bloomberg) -- Oil is heading for a fifth weekly advance, the longest winning streak since December, as stockpiles shrink and the market tightens ahead of an OPEC+ meeting that will consider pumping ...</p>\n\n<a href=\"https://finance.yahoo.com/news/oil-set-weekly-gain-focus-233523836.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://finance.yahoo.com/news/oil-set-weekly-gain-focus-233523836.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1144285047","content_text":"(Bloomberg) -- Oil is heading for a fifth weekly advance, the longest winning streak since December, as stockpiles shrink and the market tightens ahead of an OPEC+ meeting that will consider pumping more crude.\nFront-month futures in New York are up more than 2% this week and global benchmark Brent is at the highest level since October 2018. The alliance, led by Saudi Arabia and Russia, are set to meet July 1 and the group is widely expected to revive more output in August, according to a Bloomberg survey. Delegates from the coalition say discussions are already underway.\nThe rebound in fuel consumption in key regions including the U.S. and Europe is rapidly draining stockpiles, with some flagging the possibility of benchmark Brent crude hitting $100 a barrel again. The prospect of an imminent surge of Iranian oil is also diminishing as talks to revive a nuclear deal drag on.\nThe prompt timespread for Brent was 75 cents in backwardation -- where near-dated contracts are more expensive than later-dated ones. The bullish structure has eased from 85 cents at the start of the week.\nRussia is considering making a proposal that OPEC+ boost output and delegates say a hike is being informally discussed. The average gain forecast by analysts was for about 550,000 barrels a day -- barely a quarter of the global supply deficit that the alliance anticipates during August.","news_type":1,"symbols_score_info":{"CLmain":0.9}},"isVote":1,"tweetType":1,"viewCount":1288,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":128912757,"gmtCreate":1624497917979,"gmtModify":1634005259849,"author":{"id":"3577008891035439","authorId":"3577008891035439","name":"Hewx","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577008891035439","authorIdStr":"3577008891035439"},"themes":[],"htmlText":"Comment and like","listText":"Comment and like","text":"Comment and like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/128912757","repostId":"1193698944","repostType":4,"isVote":1,"tweetType":1,"viewCount":1305,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":128916720,"gmtCreate":1624497895660,"gmtModify":1634005260549,"author":{"id":"3577008891035439","authorId":"3577008891035439","name":"Hewx","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577008891035439","authorIdStr":"3577008891035439"},"themes":[],"htmlText":"Comment","listText":"Comment","text":"Comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/128916720","repostId":"1135246082","repostType":4,"isVote":1,"tweetType":1,"viewCount":1316,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":128918070,"gmtCreate":1624497838190,"gmtModify":1634005262438,"author":{"id":"3577008891035439","authorId":"3577008891035439","name":"Hewx","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577008891035439","authorIdStr":"3577008891035439"},"themes":[],"htmlText":"Comment","listText":"Comment","text":"Comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/128918070","repostId":"1115102727","repostType":4,"isVote":1,"tweetType":1,"viewCount":1229,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":123803626,"gmtCreate":1624414136765,"gmtModify":1634006458592,"author":{"id":"3577008891035439","authorId":"3577008891035439","name":"Hewx","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577008891035439","authorIdStr":"3577008891035439"},"themes":[],"htmlText":"Comment and like please","listText":"Comment and like please","text":"Comment and like please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/123803626","repostId":"1115637073","repostType":4,"isVote":1,"tweetType":1,"viewCount":1216,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":false}